<DOC>
	<DOCNO>NCT02832713</DOCNO>
	<brief_summary>In France , osteoarthritis affect 10 million people knee osteoarthritis represent 35 % case . It think 2.5 million people old 65 year knee osteoarthritis . Currently , osteoarthritis management base three major ax : 1 . Non-pharmacological mean , patient education , loss weight physical activity 2 . General pharmacological treatment : mainly paracetamol schedule II III painkiller well nonsteroidal anti-inflammatory agent . 3 . Intra-articular pharmacological treatment : 1 . Intra-articular injection corticosteroid : recommend hydarthrotic flare-up 2 . Intra-articular injection hyaluronic acid ( HA ) ( viscosupplementation ) absence intra-articular effusion . However , efficacy question expert case symptomatic knee osteoarthrosis . 4 . Sometimes , surgery therapeutic option . However , besides fact expose patient , sometimes frail , several peri- post-operative complication , recovery rate ( variable accord prosthesis type range 5 % 25 % 9 year ) age population justifies wait much possible surgery . Therefore , important test new therapeutic option symptomatic osteoarthrosis allow postpone surgical treatment . 5 . The use botulinum toxin ( BoNT-A ) could thus represent interesting alternative . BoNT-A habitually use intra-muscular injection myorelaxant effect management painful reactive periarticular muscle contracture . However , BoNT-A also antalgic activity independently myorelaxant effect . This allow explain part antalgic effect intra-articular BoNT-A injection . In literature , six randomize control study ( RCS ) compare BoNT-A intra-articular injection corticosteroid , hyaluronic acid , placebo . Only two RCS concern knee osteoarthritis compare BoNT-A corticosteroid placebo , respectively , significant antalgic effect group treat BoNT-A . No study compare yet intra-articular injection BoNT-A viscosupplementation HA knee osteoarthritis aim trial .</brief_summary>
	<brief_title>Trial Comparing Botulin Toxin Versus Hyaluronic Acid Intra-articular Injection Treatment Painful Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Painful , unilateral femorotibial knee osteoarthritis etiology Knee without clinical sign intraarticular effusion Kellgren score ( Annex VII ) ≥ II Xray image take less 6 month enrolment WOMAC pain subscore ≥ 5 week inclusion visit Clinical : Inflammatory arthropathy Neuromuscular pathology Cardiorespiratory pathology severe disease interfere functional capacity Any decompensated unstable chronic pathology Glomerular filtration rate ( GFR ) &lt; 15 mL/min/1.73m² ) HBA1c diabetic people &gt; 12 % BMI ≥ 35kg/m2 Infection : joint , general , distant , cutaneous Foreign material : prosthesis , osteosynthesis material Severe coagulation problem : platelet &lt; 100000/mm3 Allergy BoNTA Allergy HA Pregnant breastfeed woman Treatment aminoglycosides direct oral anticoagulant Treatment VKA ( antihemorrhagic vitamin ) INR ( International Normalized Ratio ) high 3 Change antipain treatment le 3 week enrolment Treatment opiates corticosteroid intense pain respond schedule I II painkiller Intraarticular injection corticosteroid previous two month Viscosupplementation and/or injection BoNTA previous 6 month Swallowing trouble</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Knee osteoarthritis</keyword>
	<keyword>Intra-articular botulinum toxin</keyword>
	<keyword>Hyaluronic acid</keyword>
	<keyword>Pain</keyword>
	<keyword>Function</keyword>
</DOC>